Norseth HML, Askeland FB, Abrahamsen I, Schjesvold F(2026) Resetting Sensitivity to T Cell Redirection by Tumor Reduction and Immune Modulation Clin Lymphoma Myeloma Leuk(in press) DOI 10.1016/j.clml.2026.01.005, PubMed 41656130
Cavo M, Schjesvold F, Dimopoulos M, Delforge M, Escalante F, Kleinman D, Lee HC, Vij R, Greil R, Melchardt T, Antonioli E, Lysen A, Camadoo-O'Byrne L, Bitetti J, D'Estrube T, Fry M, Byrne J, Vossen CY, Sapra S, Benson VS, Mouro J, Hultcrantz M(2026) Real-world effectiveness and safety of belantamab mafodotin monotherapy in patients with relapsed/refractory multiple myeloma treated in Europe Haematologica(in press) DOI 10.3324/haematol.2025.289034, PubMed 41568469
Acs K, Miettinen JJ, Sergeev P, Heckel T, Diao Y, Witt-Mulder K, Thureson M, Bischler T, Huppunen ME, Suvela M, Obermüller J, Munawar U, Slipicevic A, Bargou RC, Lehmann F, Gelius SS, Norin S, Schjesvold F, Sonneveld P, Stühmer T, Heckman CA(2025) Efficacy of melflufen in multiple myeloma with mutated or deleted TP53 Exp Hematol Oncol, 14(1), 138 DOI 10.1186/s40164-025-00729-1, PubMed 41437395
